Back

Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy in complex settings Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Julio Alejandro Lamprea Montealegre

UCSF Medical Centre, San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Effects of SGLT2i in the perioperative care of cardiac surgery: a systematic review and meta-analysis of randomised controlled trials
Mr K. Chagas (Itaperuna, BR)
Abstract
Presentation thumbnail
Cardiovascular outcomes by baseline blood pressure control status in persons with type 2 diabetes at high cardiovascular risk treated with oral semaglutide
Professor N. Poulter (London, GB)
Abstract
Presentation thumbnail
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and extra-valvular cardiac damage undergoing TAVI
Doctor G. Vincelli (Rome, IT)
Abstract
Presentation thumbnail
Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study
Doctor I. Thymis (Athens, GR)
Abstract
Presentation thumbnail
Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety
Mr J. Maldonado Flores (Tijuana, MX)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy in complex settings

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
Effect of glucagon-like peptide-1 receptor agonists on blood pressure: a systematic review and meta-analysis
4 April 2025
thumbnail
Congress Presentation
Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial
27 August 2021
thumbnail
Congress Presentation
Semaglutide and dapagliflozin synergistically prevent cancer therapy-related cardiac dysfunction in hyperglycemic conditions
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources